Living with heart conditions like Arrhythmogenic cardiomyopathy (ACM) and Brugada syndrome (BrS) brings unique challenges. A review of 30 studies shows that people with these conditions experience supraventricular tachyarrhythmias (SVT) much more often than the general population. SVT is a broad term for fast heartbeats starting in the upper chambers of the heart, such as atrial fibrillation or atrial flutter.
These rapid heartbeats are not just a nuisance. The research links them to serious clinical issues, including the progression of heart failure and an increased risk of blood clots. They can also cause inappropriate shocks from an internal defibrillator (ICD) and lead to more dangerous heart rhythms returning.
One important finding is that current tools used by doctors to predict blood clot risks may underestimate the danger for these specific patients. While the data shows a clear link between these fast heartbeats and worse outcomes, researchers note that more studies are needed to perfectly refine how we manage these risks.
Common questions
What are supraventricular tachyarrhythmias (SVT)?
SVT is a general term for fast heartbeats that start in the upper chambers of the heart. This includes conditions like atrial fibrillation and atrial flutter. In patients with Arrhythmogenic cardiomyopathy or Brugada syndrome, these rapid heartbeats occur much more frequently than in the general population.
How do these fast heartbeats affect people with heart conditions?
These rapid heartbeats are linked to several serious issues. They can lead to the progression of heart failure, an increased risk of blood clots, and a higher chance of receiving inappropriate shocks from an internal defibrillator (ICD). They may also cause dangerous ventricular arrhythmias to return.
Is the risk of blood clots accurately measured for these patients?
Current tools like the CHA2DS2-VASc score often underestimate the risk of blood clots for people with Arrhythmogenic cardiomyopathy and Brugada syndrome. Because these fast heartbeats are common in these groups, doctors must carefully consider how to manage thromboembolic risks.
